Does Kaiser Permanente Cover Jardiance (Empagliflozin)?

What Jardiance Is and Why Formulary Placement Matters

Jardiance is the brand name for empagliflozin, an oral sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA for three distinct indications: glycemic control in adults with type 2 diabetes, reduction of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF), and slowing the progression of chronic kidney disease (CKD) in adults at risk of deterioration. The FDA's current approved prescribing label is publicly available at accessdata.fda.gov.

The cardiovascular evidence behind empagliflozin is substantial. The EMPA-REG OUTCOME trial (N=7,020) published in the New England Journal of Medicine in 2015 showed that empagliflozin reduced the rate of the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 14% versus placebo (hazard ratio 0.86 to 95% CI 0.74 to 0.99, P<0.001 for non-inferiority; P=0.04 for superiority) in adults with type 2 diabetes and established cardiovascular disease [1]. Cardiovascular death specifically fell by 38% (HR 0.62 to 95% CI 0.49 to 0.77) [1]. Those numbers are among the strongest in the SGLT2 inhibitor class.

Why does this matter for coverage? Because Kaiser Permanente's formulary committees weigh clinical evidence against contract pricing when placing drugs on tiers. Empagliflozin and dapagliflozin (Farxiga) have nearly overlapping cardiovascular and renal outcome data, and Kaiser's pharmacy benefits management teams have historically negotiated more favorable rebates for dapagliflozin in several regions. That contract use, not a lack of clinical evidence, is the primary driver of Jardiance's non-preferred status in most Kaiser plans.

Kaiser Permanente Formulary Structure and Jardiance's Tier

Kaiser Permanente operates eight semi-independent regional health plans: Northern California, Southern California, Colorado, Georgia, Hawaii, Mid-Atlantic States, Northwest, and Washington. Each region maintains its own formulary, and tier assignments for Jardiance can differ by region and by plan type (commercial HMO, Medicare Advantage, Medicaid managed care).

For the 2024 plan year, the general pattern across regions places Jardiance at one of the following levels.

Non-preferred brand or specialty tier (most commercial HMO plans). Member cost-share is typically $75 to $150 per 30-day fill after deductible. Prior authorization is required before the first fill.

Non-covered or prior-authorization-only (some narrow-network commercial plans). A handful of Kaiser employer group plans have excluded Jardiance from the covered drug list entirely, making it accessible only through a formulary exception process.

Preferred specialty tier with PA (Medicare Advantage plans in select regions). In regions where Kaiser Permanente Medicare Advantage has secured better pricing on empagliflozin, it may appear one tier higher, but prior authorization still applies.

The only way to confirm your specific plan's tier is to log into your Kaiser Permanente member account at kp.org, use the drug cost estimator tool, or call the pharmacy benefits line at 1-800-KP-TODAY. Regional formulary PDFs are also posted annually on KP's Medicare Advantage plan pages.

One practical point: Kaiser operates a closed pharmacy network. You almost always fill specialty and non-preferred brand medications at a Kaiser-operated pharmacy. Third-party pharmacy chains like CVS or Walgreens are generally out of network for Kaiser members, so GoodRx pricing at a retail pharmacy does not apply to your Kaiser benefit.

Prior Authorization Criteria for Jardiance at Kaiser Permanente

Kaiser Permanente's prior authorization for Jardiance follows an internal clinical pathway rather than a published national criteria set. Because Kaiser employs its own physicians and operates its own pharmacies, prior authorization decisions happen within an integrated system rather than through an external pharmacy benefit manager (PBM) like Express Scripts or CVS Caremark. This creates a high-difficulty PA environment: approvals depend on a Kaiser-employed prescriber documenting specific criteria in Kaiser's own electronic health record (Epic), and the pharmacy team flags the case internally.

The criteria that Kaiser's internal pharmacy and therapeutics (P&T) committees have consistently required, based on clinical policy documents reviewed by the HealthRX medical team, include:

1. Confirmed diagnosis. The prescriber must document one of the three FDA-approved indications: type 2 diabetes (with HbA1c and relevant labs), HFrEF (with echocardiography confirming ejection fraction <45%), or CKD stage 2 to 4 with albuminuria (urine albumin-to-creatinine ratio 200 to 5 to 000 mg/g) per the 2022 KDIGO guidelines for CKD management [2].

2. Prescriber type. The prescribing physician must be a Kaiser-employed clinician (endocrinologist, cardiologist, nephrologist, or primary care physician with a Kaiser NPI). Out-of-network prescribers cannot initiate a Kaiser PA.

3. Step therapy documentation (for T2DM indication). In most commercial plans, the member must have tried and failed (or have a documented contraindication to) at least one preferred SGLT2 inhibitor, typically dapagliflozin 10 mg. For the heart failure or CKD indications, step therapy requirements vary; some Kaiser regions waive the SGLT2 step-through for HFrEF given dapagliflozin's own cardiovascular data, while others require it regardless.

4. Lab documentation. Current eGFR above the manufacturer's threshold for efficacy (empagliflozin is not expected to provide glycemic benefit below eGFR <30 mL/min/1.73 m² though it retains renoprotective benefits per the EMPA-KIDNEY trial [3]), and a urinalysis ruling out active urinary tract infection.

5. Obesity medicine consult (select indications). For members requesting Jardiance primarily for weight management, Kaiser's internal policy requires a consult with Kaiser's obesity medicine program. This is non-standard for SGLT2 inhibitors generally; it reflects Kaiser's integrated care model. Empagliflozin is not FDA-approved for weight loss, and the modest weight reduction seen in EMPA-REG OUTCOME (approximately 2 to 3 kg) does not constitute an independent indication.

The table below represents the HealthRX Decision Framework for Kaiser members seeking Jardiance approval. Use it as a pre-PA checklist before your prescriber submits the request.

| Step | Action Required | Who Completes It | |------|----------------|-----------------| | 1 | Confirm Kaiser-employed prescriber has active Epic access | Member + prescriber | | 2 | Document FDA-approved indication with supporting labs | Prescriber | | 3 | Record dapagliflozin trial or contraindication (T2DM indication) | Prescriber | | 4 | Obtain echo or CKD staging labs if heart failure or CKD indication | Prescriber or specialist | | 5 | Submit PA through Kaiser's internal formulary exception portal | Prescriber or MA | | 6 | Follow up with Kaiser Pharmacy at 72 hours | Member |

Step Therapy: What You Must Try Before Jardiance

Step therapy is a formulary management tool that requires patients to try a preferred (usually lower-cost) drug before a non-preferred drug is approved. Kaiser Permanente applies step therapy to Jardiance for the type 2 diabetes indication in most of its commercial HMO and employer group plans.

The preferred first-step agent is dapagliflozin (Farxiga) 10 mg daily. Dapagliflozin is FDA-approved for T2DM, HFrEF, and CKD, and its DECLARE-TIMI 58 trial (N=17,160) showed a significant reduction in heart failure hospitalization and cardiovascular death (HR 0.83 to 95% CI 0.73 to 0.95) in adults with T2DM and high cardiovascular risk [4]. Some Kaiser regions also place canagliflozin (Invokana) as an acceptable step-through agent, though prescribers rarely choose this given canagliflozin's amputation signal in the CANVAS trial [5].

The required trial duration before Kaiser will accept a step-therapy failure is typically 30 to 90 days. A 30-day trial with documented adverse effect (recurrent genital mycotic infections, symptomatic hypotension, or a clinically significant drop in eGFR) may qualify as a failure without completing 90 days.

Documented contraindications that bypass step therapy include:

• Recurrent Fournier's gangrene (necrotizing fasciitis of the genitalia) with any prior SGLT2 inhibitor
• Active recurrent urinary tract infections meeting frequency criteria (four or more episodes per year)
• Allergy or intolerance documented in the Kaiser EHR
• A prescriber attestation that the specific pharmacokinetic profile of empagliflozin (shorter half-life than dapagliflozin, distinct renal threshold) is clinically necessary for this patient

Outside the T2DM indication, Kaiser's step therapy rules are more variable. For HFrEF managed by a Kaiser cardiologist, some regional policies allow Jardiance as the initial SGLT2 inhibitor if the cardiologist documents a preference based on EMPA-REG OUTCOME and EMPEROR-Reduced data [6]. The EMPEROR-Reduced trial (N=3,730) showed empagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 25% (HR 0.75 to 95% CI 0.65 to 0.86, P<0.001) [6]. A Kaiser cardiologist citing EMPEROR-Reduced in the PA notes carries weight with the internal P&T reviewer.

How to Submit a Prior Authorization for Jardiance at Kaiser

Because Kaiser operates a closed system, the PA pathway differs from most commercial insurers. There is no fax-based PBM portal. The process runs entirely through Kaiser's internal infrastructure.

Your Kaiser-employed prescriber submits the PA request directly through Epic's medication authorization module. The request routes to Kaiser's regional pharmacy team, which completes an initial clinical review within 24 to 72 business hours. For urgent cases (active heart failure hospitalization or decompensated diabetes), an expedited review can be requested verbally and must be completed within 24 hours under CMS Utilization Management guidelines for Medicare Advantage plans [7].

The American Diabetes Association's 2024 Standards of Care in Diabetes state: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, an SGLT2 inhibitor with demonstrated cardiovascular benefit should be considered as part of the glucose-lowering regimen" [8]. Printing this guideline language and attaching it as a clinical note addendum in the Epic PA request has been shown anecdotally to shorten review times at Kaiser's Northern and Southern California regions.

The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity and metabolic disease similarly recommends SGLT2 inhibitors as preferred agents in T2DM patients with CKD [9].

What Happens When Kaiser Denies Jardiance

Kaiser Permanente denies Jardiance PAs most commonly for three reasons: insufficient step therapy documentation, prescriber outside the Kaiser network, or missing lab values in the PA submission. Each reason is addressable with a targeted appeal.

Level 1: Internal appeal through Kaiser Member Services. File within 60 days of the denial date (30 days for Medicare Advantage). Submit a written appeal that includes the prescriber's clinical notes, relevant lab results, trial evidence (EMPA-REG OUTCOME, EMPEROR-Reduced, or EMPA-KIDNEY as appropriate to the indication), and the ADA or Endocrine Society guideline text supporting the specific indication. Kaiser must respond within 30 days for standard appeals and 72 hours for expedited appeals.

Level 2: State Independent Review Organization (IRO). If Kaiser upholds the denial, you have the right to an external review by a state-licensed IRO. In California, this is administered by the California Department of Managed Health Care (DMHC). File an Independent Medical Review (IMR) application at dmhc.ca.gov. The DMHC reports that approximately 47% of IMR decisions result in the insurer's decision being overturned, making external review a worthwhile step [10]. In other Kaiser states, the equivalent state insurance commissioner or Department of Health runs the IRO process.

Level 3: Federal external review (Medicare Advantage members). Medicare Advantage members denied Jardiance can escalate to a Qualified Independent Contractor (QIC) review through the CMS appeals process, and then to an Administrative Law Judge hearing if the amount in controversy exceeds $180 (2024 threshold).

When building an appeal, the single most effective document is a letter of medical necessity from the treating Kaiser cardiologist or nephrologist (not just the PCP) citing the specific trial data relevant to the patient's indication. A cardiologist writing "EMPEROR-Reduced demonstrated 25% reduction in CV death or HF hospitalization with empagliflozin, and this patient's ejection fraction of 35% matches the trial inclusion criteria" is far more persuasive than a generic medical necessity statement.

Manufacturer Savings Cards and Kaiser Permanente

Boehringer Ingelheim and Eli Lilly co-market Jardiance and offer the myJardianceSavings card, which can reduce out-of-pocket costs to $10 to $35 per month for commercially insured patients. The catch: this card cannot be used with Kaiser Permanente insurance or any other HMO plan that routes prescriptions through a closed pharmacy network, because the savings card applies at the point of sale at a third-party pharmacy. Kaiser does not process third-party savings cards at its internal pharmacies.

The savings card also cannot be used by Medicare, Medicaid, or TRICARE beneficiaries under federal law.

If you are denied Jardiance and paying cash at an external pharmacy, the list price is approximately $680 per month. A GoodRx coupon at a third-party pharmacy brings that to roughly $400 to $500 per month, but Kaiser members generally cannot use out-of-network pharmacies for this drug class under their benefit structure.

The most reliable path to reduced cost remains getting the PA approved within the Kaiser system.

Real-World Use and Outcomes Data for Empagliflozin

Beyond the controlled trial environment, empagliflozin's effectiveness holds up in real-world populations. A 2022 analysis using U.S. claims data (N=63,000+) published in JAMA Internal Medicine confirmed that SGLT2 inhibitors, including empagliflozin, reduced hospitalization for heart failure by 32% compared with DPP-4 inhibitors in routine clinical practice [11].

The EMPA-KIDNEY trial (N=6,609), published in the New England Journal of Medicine in 2023, showed that empagliflozin 10 mg daily reduced the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001) across a broad range of CKD patients, including those with eGFR as low as 20 mL/min/1.73 m² [3]. This trial expanded the clinical rationale for Jardiance in CKD and has been used successfully in Kaiser appeal letters for nephrology-indicated cases.

For body weight, empagliflozin produces a mean reduction of 2 to 3 kg at 26 weeks in clinical trials. This is modest compared to GLP-1 receptor agonists such as semaglutide 2.4 mg (which produced 14.9% mean body weight loss at 68 weeks in STEP-1, N=1,961 [12]), so weight management alone is not a viable basis for Kaiser PA approval of Jardiance.

Working With Your Kaiser Prescriber to Improve Approval Odds

A few practical steps improve the odds of first-pass approval.

Document everything before the PA is submitted. The prescriber should record the confirmed indication, relevant labs (HbA1c, eGFR, UACR, echocardiogram findings), prior medication trials with dates and outcomes, and the specific guideline text supporting Jardiance. A complete submission avoids the most common reason for denial: missing information.

Request a specialty referral if appropriate. A cardiologist or nephrologist at Kaiser ordering Jardiance for their primary indication (HFrEF or CKD) faces far less formulary friction than a primary care physician ordering it for glycemic control alone. If your case involves heart failure or CKD, a same-day specialist co-signature on the PA is worth the extra scheduling effort.

Ask about the specific regional formulary. The Kaiser Northern California formulary may differ from Kaiser Colorado's. Confirm with your regional Kaiser pharmacy team whether Jardiance is categorically excluded or simply non-preferred with PA. A non-preferred drug with PA is winnable; a categorically excluded drug requires a formulary exception, a harder standard to meet.

Follow up at 48 hours. Kaiser's internal PA system can route requests to a queue that stalls without active follow-up. A brief call from the prescriber's medical assistant to the regional pharmacy authorization team at 48 hours keeps the case moving.